An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Sponsor
PDL BioPharma, Inc. (Industry)
Overall Status
Terminated
CT.gov ID
NCT00355901
Collaborator
(none)
300
40
74
7.5
0.1
Study Details
Study Description
Brief Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
300 participants
Time Perspective:
Prospective
Official Title:
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Study Start Date
:
Sep 1, 2006
Study Completion Date
:
Nov 1, 2012
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Previous participation in a visilizumab study of IVSR-UC.
-
Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy.
Exclusion Criteria:
-
Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent.
-
For U.S. sites, unwilling or unable to provide authorization to use protected health information.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | San Francisco | California | United States | 94115 | |
2 | Gainesville | Florida | United States | 32610 | |
3 | Atlanta | Georgia | United States | 30342 | |
4 | Louisville | Kentucky | United States | 40202 | |
5 | Worcester | Massachusetts | United States | 01655 | |
6 | Rochester | Minnesota | United States | 55905 | |
7 | St. Louis | Missouri | United States | 63110 | |
8 | Manhasset | New York | United States | 11030 | |
9 | Mineola | New York | United States | 11501 | |
10 | New York | New York | United States | 10021 | |
11 | New York | New York | United States | 10029 | |
12 | Cleveland | Ohio | United States | 44106 | |
13 | Hershey | Pennsylvania | United States | 17033 | |
14 | Charleston | South Carolina | United States | 29425 | |
15 | Salt Lake City | Utah | United States | 84107 | |
16 | Bedford Park | South Australia | Australia | ||
17 | Box Hill | Victoria | Australia | ||
18 | Fremantle | Australia | 6160 | ||
19 | Liverpool | Australia | 2170 | ||
20 | Wien | Austria | A-1090 | ||
21 | Ghent | Belgium | B-9000 | ||
22 | Leuven | Belgium | 3000 | ||
23 | Roeselare | Belgium | 8800 | ||
24 | Winnipeg | Manitoba | Canada | R3A-139 | |
25 | Hamilton | Ontario | Canada | L8N 3Z5 | |
26 | Brno | Czech Republic | |||
27 | Praha | Czech Republic | |||
28 | Amiens Cedex | France | 80054 | ||
29 | Lille | France | 59037 | ||
30 | Paris | France | 75010 | ||
31 | Freiburg | Germany | D-79106 | ||
32 | Béri Balogh Adám | Hungary | H-7100 | ||
33 | Vac | Hungary | H-2601 | ||
34 | Vásvari Pál | Hungary | H-9024 | ||
35 | Dublin | Ireland | |||
36 | Bologna | Italy | 40138 | ||
37 | Amsterdam | Netherlands | 1105 AZ | ||
38 | Oslo | Norway | |||
39 | Tromso | Norway | |||
40 | Kharkov | Ukraine | 61001 |
Sponsors and Collaborators
- PDL BioPharma, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00355901
Other Study ID Numbers:
- 291-420
First Posted:
Jul 25, 2006
Last Update Posted:
Aug 5, 2008
Last Verified:
Aug 1, 2008
Keywords provided by ,
,
Additional relevant MeSH terms: